Related Experiment Video
Updated: Jan 23, 2026

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
Published on: October 5, 2020
Harmine suppresses hyper-activated Ras-MAPK pathway by selectively targeting oncogenic mutated Ras/Raf in
Jiaojiao Ji1, Jiang Yuan1, Xiaoyu Guo1
11Beijing University of Chinese Medicine, Beijing, China.
Background:
Mutationally activated Ras proteins are closely linked to a wide variety of human cancers. Hence, there has been an intensive search for anti-Ras therapies for cancer treatment. The sole Ras gene, which encodes LET-60, in Caenorhabditis elegans regulates vulval development. While the loss of let-60 function leads to failure of vulva formation, the let-60(n1046gf) allele, which contains a missense mutation mimicking a Ras codon 13 mutation found in human cancers, results in extra vulval tissue, a phenotype named Muv (multiple vulvas).
Methods:
By taking advantage of the easy-to-score Muv phenotype of let-60(n1046gf), we used a step-by-step screening approach (from crude extract to active fraction to active natural compound) to search for inhibitors of oncogenic Ras. Mutants of other key components in the Ras-mitogen-activated protein kinase (MAPK) pathway were used to identify other candidate targets.
Results:
The natural compound harmine, isolated from the plant Peganum harmala, was found to suppress the Muv phenotype of let-60(n1046gf). In addition, harmine targets the hyper-activation of the Ras/MAPK pathway specifically caused by overexpression or mutated forms of LET-60/Ras and its immediate downstream molecule LIN-45/Raf. Finally, harmine can be absorbed into the worm body and probably functions in its native form, rather than requiring metabolic activation.
Conclusion:
In sum, we have revealed for the first time the anti-Ras activity of harmine in a C. elegans model system. Our results revealed the potential anti-cancer mechanism of harmine, which may be useful for the treatment of specific human cancers that are associated with oncogenic Ras mutations.
Insights
Harmine, a natural compound, shows anti-Ras activity by suppressing cancer-promoting mutations in a C. elegans model. This finding suggests harmine
Area of Science:
- Molecular Biology
- Genetics
- Pharmacology
Background:
- Oncogenic Ras mutations drive numerous human cancers, necessitating the development of anti-Ras therapies.
- The Ras pathway, including LET-60/Ras, is crucial for development in *C. elegans*, with specific mutations causing phenotypes like Muv (multiple vulvas).
Purpose of the Study:
- To identify natural compounds that inhibit oncogenic Ras activity.
- To investigate the anti-Ras potential of harmine using a *C. elegans* model.
Main Methods:
- A screening approach was employed using the *let-60*(n1046gf) Muv phenotype in *C. elegans* to identify Ras inhibitors.
- The Ras-mitogen-activated protein kinase (MAPK) pathway components were analyzed to pinpoint harmine's targets.
- Harmine's absorption and activity in *C. elegans* were assessed.
Main Results:
- Harmine, isolated from *Peganum harmala*, suppressed the Muv phenotype in *let-60*(n1046gf) mutants.
- Harmine specifically targeted hyper-activation of the Ras/MAPK pathway caused by mutated LET-60/Ras and LIN-45/Raf.
- Harmine is absorbed and functions in its native form within the worm.
Conclusions:
- This study demonstrates the anti-Ras activity of harmine in a *C. elegans* model.
- Harmine's mechanism offers potential for treating human cancers driven by oncogenic Ras mutations.
Related Concept Videos
The Ras Gene
Ras is a...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Mutations
MAPK Signaling Cascades
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Viral Mutations

